Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Triplebody development process

Georg Fey • 15 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies SPM-2

Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the development of the lead triplebody candidate and the manufacturing process. Prof. Fey highlights the catch 42 the team are facing in moving this agent into trials, due to the external effector cells that the therapy utilizes. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Georg Fey

The benefits of dual-targeting triplebodies
2:03
The benefits of dual-targeting triplebodies
Georg Fey • 15 Mar 2019
Triplebodies for AML: origin, rationale & development
3:57
Triplebodies for AML: origin, rationale & development
Georg Fey • 15 Mar 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals